This laboratory is interested in the development of novel instrumentation and software algorithms for in vivo imaging of molecular signals in humans and small laboratory animals. The goals of the instrumentation projects are to push the sensitivity and spatial, spectral, and/or temporal resolutions as far as physically possible. The algorithm goals are to understand the physical system comprising the subject tissues, radiation transport, and imaging system, and to provide the best available image quality and quantitative accuracy. The work involves computer modeling, position sensitive sensors, readout electronics, data acquisition, image formation, image processing, and data/image analysis algorithms, and incorporating these innovations into practical imaging devices. The ultimate goal is to introduce these new imaging tools into studies of molecular mecha- nisms and treatments of disease within living subjects.
Dr. Nieman is a cardiologist and associate professor in the departments of Cardiovascular Medicine and Radiology. He investigates advanced cardiac imaging techniques, and current projects include the development and technical validation of functional CT applications for ischemic heart disease, and the clinical validation of cardiac CT in the form of clinical effectiveness trials.
Our clinical research in Medical Oncology is an integrated program that leverages the scientific and clinical expertise at Stanford. Phase I trials sit at the interface of laboratory advances and later stage clinical development; expedite development of new treatments while ensuring patient safety; and provide the basis to prioritize resource allocation and inform rational drug development strategies. The program conducts trials that provide proof of mechanism, proof of principle, and proof of concept early in the process of developing novel therapeutics. One of our research interests is to use imaging to evaluate drug pharmacokinetics and target modulation.
This laboratory focuses on advancing radiopharmaceutical sciences for the expanding field of molecular imaging. We design and synthesize novel radioligands/radiotracers that bind to molecular targets related to specific nervous system (central and peripheral) disorders and cancer biology. In addition, new radiolabeling techniques and methodologies will be created in our lab for emerging radiopharmaceutical development as well as for the general radiochemistry community. These radiochemistry approaches will be coupled with innovative chemical engineering to further investigate new molecular imaging strategies. Successful imaging agents will also be extended towards future human clinical applications.